Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
ConditionPancreatic Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.
Eligibility criteria
Qualifiers
2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
OR 2+ affected first degree relatives [(FDR), defined as blood related parents, siblings, or children]
CDKN2A/p16, Peutz-Jeghers syndrome (PJS) serine/threonine kinase 11 (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53
Disqualifiers
Is unable to provide informed consent
Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)
Current or prior history of PDAC or total pancreatectomy
Is currently a prison inmate
Trial design
Treatments tested in this trial
- Non-Interventional Study
Treatment groups
30,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Mayo Clinic
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov